日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

利用T细胞结合双特异性抗体治疗细胞因子释放综合征的临床药理学：最新进展和药物研发策略

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2247
Radtke, Kendra K; Bender, Brendan C; Li, Zao; Turner, David C; Roy, Sumedha; Belousov, Anton; Li, Chi-Chung
细胞生物学
T细胞
T细胞
免疫/内分泌
发表日期：2025
文献求助 收藏

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

一种提高莫苏妥珠单抗治疗复发或难治性滤泡性淋巴瘤获益风险比的新型递增剂量方案

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3445
Li, Chi-Chung; Bender, Brendan; Wilkins, Justin; Li, Feifei; Turner, David C; Wang, Bei; Deng, Rong; Vadhavkar, Shweta; Li, Zao; Kwan, Antonia; Huang, Huang; Peng, Kun; Penuel, Elicia; Huw, Ling-Yuh; Chanu, Pascal; Li, Chunze; Yin, Shen; Wei, Michael C
淋巴瘤
发表日期：2025
文献求助 收藏

Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500

更正：Susilo 等人，《基于生理的全身药代动力学模型框架用于 CD3 双特异性抗体的组织靶点结合》，Pharmaceutics 2025, 17, 500

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics18010012
Susilo, Monica E; Schaller, Stephan; Jiménez-Franco, Luis David; Kulesza, Alexander; de Witte, Wilhelmus E A; Chen, Shang-Chiung; Boswell, C Andrew; Mandikian, Danielle; Li, Chi-Chung
CD3
发表日期：2025
文献求助 收藏

Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies

基于全身生理的CD3双特异性抗体组织靶点结合药代动力学建模框架

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics17040500
Susilo, Monica E; Schaller, Stephan; Jiménez-Franco, Luis David; Kulesza, Alexander; de Witte, Wilhelmus E A; Chen, Shang-Chiung; Boswell, C Andrew; Mandikian, Danielle; Li, Chi-Chung
CD3
发表日期：2025
文献求助 收藏

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

莫苏妥珠单抗在中国复发或难治性滤泡性淋巴瘤患者中的药代动力学和药效学的种族敏感性评估

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70211
Li Junyi, Liao Michael Z, Wilkins Justin, Penuel Elicia, Wang Bei, Vadhavkar Shweta, Peng Kun, Cao Junning, Li Zhiming, Zhang Ye, Li Wenjin, Li Donghang, Zhou Mingzhu, Wei Michael C, Kwan Antonia, Zhao Rong, Li Chunze, Li Chi-Chung, Turner David C
肿瘤
淋巴瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling

利用基于生理的药代动力学模型评估莫苏妥珠单抗通过细胞因子（IL-6）升高介导的CYP3A药物相互作用

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13073
Chen, Yuan; Ma, Fang; Jones, Nicholas; Deng, Rong; Li, Chunze; Li, Chi-Chung
细胞生物学
IL-6
免疫/内分泌
发表日期：2024
文献求助 收藏

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma

莫苏妥珠单抗在复发/难治性B细胞非霍奇金淋巴瘤中的群体药代动力学和CD20结合动力学

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13825
Bender, Brendan; Li, Chi-Chung; Marchand, Mathilde; Turner, David C; Li, Feifei; Vadhavkar, Shweta; Wang, Bei; Deng, Rong; Lu, James; Jin, Jin; Li, Chunze; Yin, Shen; Wei, Michael; Chanu, Pascal
B细胞
细胞生物学
免疫/内分泌
淋巴瘤
CD2
CD20
发表日期：2024
文献求助 收藏

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

莫苏妥珠单抗单药治疗对复发/难治性弥漫性大B细胞淋巴瘤患者有效且耐受性良好

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2022009260
Bartlett, Nancy L; Assouline, Sarit; Giri, Pratyush; Schuster, Stephen J; Cheah, Chan Y; Matasar, Matthew; Gregory, Gareth P; Yoon, Dok Hyun; Shadman, Mazyar; Fay, Keith; Yoon, Sung-Soo; Panizo, Carlos; Flinn, Ian; Johnston, Anna; Bosch, Francesc; Sehn, Laurie H; Wei, Michael C; Yin, Shen; To, Iris; Li, Chi-Chung; Huang, Huang; Kwan, Antonia; Penuel, Elicia; Budde, Lihua E
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2023
文献求助 收藏

Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL

在一项针对非霍奇金淋巴瘤的双特异性抗体 mosunetuzumab 的 I 期研究中，基于系统的数字孪生技术将帮助表征临床剂量反应并提出预测性生物标志物。

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13501
Susilo, Monica E; Li, Chi-Chung; Gadkar, Kapil; Hernandez, Genevive; Huw, Ling-Yuh; Jin, Jin Y; Yin, Shen; Wei, Michael C; Ramanujan, Saroja; Hosseini, Iraj
淋巴瘤
发表日期：2023
文献求助 收藏

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab

难治性Hailey-Hailey病经局部鲁索替尼乳膏和度普利尤单抗治疗后获得成功

期刊:JAAD Case Reports
影响因子:
doi:10.1016/j.jdcr.2023.10.004
Khang, Juna; Yardman-Frank, J Michael; Chen, Li-Chi; Chung, Hye Jin
发表日期：2023
文献求助 收藏